Success Story: Overcoming RFE to Advance Genomic Research for Targeted Cancer Therapies: NIW Approval Secured for a Bioinformatics Researcher from Turkey
Client’s Testimonial:
"I appreciate the service you have provided and am very grateful for your dedication throughout this process.”
On September 30th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Fellow in the field of Bioinformatics (Approval Notice).
General Field: Bioinformatics
Position at the Time of Case Filing: Postdoctoral Fellow
Country of Origin: Turkey
State of Residence at the Time of Filing: Indiana
Approval Notice Date: September 30th, 2026
Processing Time: 1 year, 10 months, 26 days (Premium Processing Requested)
Case Summary:
We are pleased to share the NIW approval of a bioinformatics researcher whose work focuses on analyzing large-scale genomic data to better understand the biology of complex diseases, including cancer. The client’s proposed endeavor aims to use genomic and multi-omics approaches to support the development of more targeted, less toxic, and effective cancer therapies while helping address disparities in cancer outcomes. At the time of filing, the client was conducting research at a U.S. university, where his work involved cancer genomics, precision oncology, biomarker discovery, and the analysis of large-scale biological datasets.
Research with National Importance
The client’s research addresses the need for improved cancer treatments and a deeper understanding of the molecular factors that influence disease progression and treatment response. By analyzing genomic and multi-omics data, his work can help identify biomarkers, clarify differences among cancer subtypes and patient populations, and support the development of more precise treatment strategies. The petition further connected his endeavor to U.S. priorities involving cancer care, health disparities, biotechnology, bioinformatics, computational biology, and precision medicine.
Academic Contributions and Recognition
At the time of filing, the client had documented his research in 12 peer-reviewed journal articles, 3 peer-reviewed conference articles, 1 preprint, 3 abstracts, and 1 book chapter. His published work had received 240 citations. He had also completed at least 13 peer reviews for scholarly journals and conferences, demonstrating recognition of his expertise in genomic and proteomic data analysis, cancer research, biomarker discovery, and related areas of bioinformatics.
The petition further demonstrated the client’s significance through the citation impact and independent use of his research. Two of his papers ranked among the top 1% and two others among the top 10% most-cited articles in Molecular Biology & Genetics for their respective years of publication. Independent researchers had also relied on his findings in studies involving cancer classification, therapeutic target discovery, immunotherapy response, gene-network analysis, and treatment resistance, further demonstrating the influence of his research on cancer biology and computational methods.
NIW Approval and Outlook
The I-140 NIW petition was filed on November 4th, 2024, later upgraded to Premium Processing, and received an RFE on May 13th, 2026. The petition was subsequently approved on September 30th, 2026. The approval recognized the national importance of the client’s work in applying bioinformatics and large-scale genomic analysis to cancer research, targeted therapy development, and efforts to reduce disparities in cancer care.
This outcome supports the client’s continued efforts to apply computational and multi-omics approaches to improve understanding of cancer biology and support precision oncology. We congratulate him on this approval and wish him continued success in his research.